Brought to you by 
LeukoSite and Roche Bioscience work on asthma and allergies
13 Jul 1999
Executive Summary
LeukoSite (inflammatory and autoimmune diseases) and Roche Bioscience will collaborate to research and develop new treatments for asthma and allergic disorders based on LeukoSite's knowledge of eosinophil chemokine receptors.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
LeukoSite and Roche Bioscience work on asthma and allergies
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice